BeOne Medicines AG (ONC)

NMS – Real vaqt narxi. Valyuta: USD

279.89

+4.55 (1.65%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

279.89

0.00 (0.00%)

Bozordan keyin: Jun 26, 2026, 4:10 PM EDT

12.06.2026

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton's tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic.

11.06.2026

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibr.

08.06.2026

BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

05.06.2026

BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?

BeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

02.06.2026

BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO Transcript

02.06.2026

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

BeOne Medicines NASDAQ: ONC used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company said are moving toward registrational development.

01.06.2026

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines' Tevimbra immunotherapy.

Videolar

No Data

There is no data to display

Press-relizlar

12.06.2026

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

11.06.2026

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

01.06.2026

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company's high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. Data from three differentiated Be.

29.05.2026

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further suppo.

BeOne Medicines AG (ONC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BeOne Medicines AG (ONC)

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?

BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO Transcript

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Videolar

No Data

Press-relizlar

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?

BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO Transcript

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Videolar

No Data

Press-relizlar

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

Search stocks

BeOne Medicines AG (ONC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BeOne Medicines AG (ONC)

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?

BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO Transcript

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Videolar

No Data

Press-relizlar

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?

BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO Transcript

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Videolar

No Data

Press-relizlar

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026